Data as of Dec 19
| +0.70 / +0.60%|
The 23 analysts offering 12-month price forecasts for Celgene have a median target of 120.21, with a high estimate of 145.00 and a low estimate of 66.00. The median estimate represents a +2.59% increase from the last price of 117.18.
The current consensus among 27 polled investment analysts is to Buy stock in Celgene. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.